Previous Article | Next Article 
Journal of Virology, April 2000, p. 3859-3870, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Block to Human Immunodeficiency Virus Type 1 Assembly in Murine Cells
Roberto
Mariani,1
Gabriel
Rutter,2
Matthew E.
Harris,1
Thomas J.
Hope,1
Hans-Georg
Kräusslich,2 and
Nathaniel R.
Landau1,*
Infectious Disease Laboratory, The Salk
Institute for Biological Studies, La Jolla, California
92037,1 and Heinrich-Pette-Institut,
Hamburg, Germany2
Received 12 November 1999/Accepted 12 January 2000
 |
ABSTRACT |
Human immunodeficiency virus type 1 (HIV-1) does not replicate in
murine cells. We investigated the basis of this block by infecting a
murine NIH 3T3 reporter cell line that stably expressed human CD4,
CCR5, and cyclin T1 and contained a transactivatable HIV-1 long
terminal repeat (LTR)-green fluorescent protein (GFP) cassette.
Although the virus entered efficiently, formed provirus, and was
expressed at a level close to that in a highly permissive human cell
line, the murine cells did not support M-tropic HIV-1 replication. To
determine why the virus failed to replicate, the efficiency of each
postentry step in the virus replication cycle was analyzed using
vesicular stomatitis virus G pseudotypes. The murine cells supported
reverse transcription and integration at levels comparable to those in
the human osteosarcoma-derived cell line GHOST.R5, and human cyclin T1
restored provirus expression, consistent with earlier findings of
others. The infected murine cells contained nearly as much virion
protein as did the human cells but released less than 1/500 the amount
of p24gag into the culture medium. A small
amount of p24gag was released and was in the
form of fully infectious virus. Electron microscopy suggested that
aberrantly assembled virion protein had accumulated in cytoplasmic
vesicular structures. Virions assembling at the cell membrane were
observed but were rare. The entry of M-tropic JR.FL-pseudotyped
reporter virus was moderately reduced in the murine cells, suggesting a
minor reduction in coreceptor function. A small reduction in the
abundance of full-length viral mRNA transcripts was also noted;
however, the major block was at virion assembly. This could have been
due to a failure of Gag to target to the cell membrane. This block must
be overcome before a murine model for HIV-1 replication can be developed.
 |
INTRODUCTION |
Several murine models have been
developed for studies of AIDS pathogenesis. Mice transgenic for either
the entire or partial human immunodeficiency virus type 1 (HIV-1)
genome develop symptoms with similarities to AIDS. In one model, mice
expressing HIV-1 Nef developed a wasting syndrome characterized by the
loss of CD4+ cells (21, 45). In another model,
SCID mice were reconstituted with human peripheral blood lymphocytes or
fetal thymus and liver and then inoculated with HIV-1 (37).
These have been useful for studies on mechanisms of CD4+
cell depletion and for evaluation of therapeutic strategies.
Current murine models lack a central feature of HIV-1-induced
pathogenesis: virus replication. Inoculation of mice or rodents such as
rats, hamsters, and guinea pigs with high-titer HIV-1 does not result
in detectable viremia, nor does the virus replicate in murine cells in
culture (37) or infect human-CD4 (hu-CD4) transgenic mice
(33). Low levels of virus replication have been detected in
experimentally infected rabbits (13, 15, 20, 26, 43) and
cotton rats (30), but this does not induce pathogenesis. Development of a system in which HIV-1 could replicate in mice would
allow the investigation of features of AIDS such as the immune response
to the virus, the dynamics of virus replication, and the mechanism of
T-cell depletion. It would also make available the wide range of
serological reagents and the well-characterized genetics in the murine system.
HIV-1 fails to replicate in murine cells for several reasons, the best
studied of which is the block to virus entry. The HIV-1 envelope
glycoprotein (Env) binds with high affinity to hu-CD4 but does not bind
measurably to murine (mu-CD4) (29). In addition, HIV-1 Env
fails to interact with mu-CCR5 (2). Unexpectedly, some
T-tropic HIV-1 Env proteins are able to use mu-CXCR4 for infection
(5, 48). Coexpression of transfected hu-CD4 and hu-CCR5 or
hu-CXCR4 in murine cells in culture allows the entry of HIV-1
(4). Alternatively, the entry block can be circumvented by
pseudotyping HIV-1 with amphotropic Moloney murine leukemia virus Env
or vesicular stomatitis virus G (VSV-G), which allows entry through
different receptors. In mice transgenic for hu-CD4 and hu-CCR5
(8) or hu-CXCR4 (44), inoculation with HIV-1 resulted in a small number of infected cells but no detectable viremia.
In contrast, rabbit cells expressing transfected hu-CD4 and hu-CCR5 are
permissive for robust HIV-1 replication (47).
In addition to the entry block in murine cells, HIV-1 long terminal
repeat (LTR)-directed transcription is inefficient in murine cells due
to weak Tat activity in rodent cells (1). Using transfected
reporter constructs, transactivation of LTR transcription by Tat was
10- to 25-fold less active in rodent cells. The deficiency in Tat
function in rodent cells could be complemented in rodent/human somatic
cell hybrids containing human chromosome 12 (1, 23, 38). The
active gene was recently identified as cyclin T1 (51), a
partner for the cyclin-dependent kinase CDK9 in the transcription
elongation factor P-TEFb (19, 34, 55). Cyclin-T1/CDK9 binds
the TAR transactivation region of nascent HIV-1 transcripts, promoting
hyperphosphorylation of serine and threonine residues in the
cytoplasmic tail domain of RNA polymerase II (reviewed in reference
17). Phosphorylation increases the processivity of
the transcription complex, allowing the synthesis of the full-length
HIV-1 primary RNA transcript. Mu-cyclin T1 is competent to bind Tat,
but the resulting complex fails to bind TAR, a phenotype that results
from the presence of a tyrosine in place of cysteine at residue 261 (7, 18, 27). Transfection of a human cyclin T1 (hu-cyclin
T1) expression vector restored Tat function in rodent cells in an HIV-1
LTR reporter vector assay and in infected murine cells (7, 18, 27,
51).
Murine NIH 3T3 cells expressing transfected hu-CD4, hu-CCR5, and
hu-cyclin T1 failed to support HIV-1 replication (18). While
the cyclin T1 allowed for more efficient expression of the HIV-1
provirus, infected cells produced only low levels of
p24gag, suggesting the presence of additional
blocks to HIV-1 replication in the murine cells. Here we investigated
the basis of this additional block in the murine cells by measuring the
efficiency of each step of virus replication in NIH 3T3 reporter cells
expressing these three human cofactors. Consistent with earlier
findings (18), the murine cells were not permissive for
HIV-1 replication; however, they efficiently supported several of the
steps in the virus life cycle. Virion structural proteins were
expressed at high level but, instead of assembling at the cell
membrane, were trapped in cytoplasmic vesicular structures. As a
result, Gag was poorly processed and virions were released only at low
levels. Interestingly, the small amount of Gag protein that was
released from the cells was in the form of infectious virus, suggesting that the block to replication in murine cells is not absolute.
 |
MATERIALS AND METHODS |
Derivation of murine and human reporter cell lines.
Murine
reporter cells were derived by transfecting NIH 3T3 cells with plasmid
pLTR-EGFP-1, which contains the HIV-1 LTR linked to the enhanced green
fluorescent protein (EGFP) gene. Transfectants were selected in medium
(Dulbecco's modified Eagle's medium plus 10% fetal bovine serum)
containing 0.4 mg of G418 per ml. The resulting drug-resistant
population was sorted by fluorescence-activated cell sorting (FACS) for
those expressing low but detectable green fluorescence. The sorted
cells were then infected with pBABE-CCR5 retroviral vector stock and
selected 2 days later in medium containing 0.2 µg of puromycin per
ml. Puromycin-resistant cells were sorted by FACS for those that
stained with the anti-CCR5 monoclonal antibody 2D7 (Pharmingen). The
cells were then infected with the retroviral vector pMX-CD4, based on
the vector pMX (39), that contains hu-CD4 but no selectable
marker. CD4 expressing cells were selected on anti-CD4-coated magnetic
beads (Dynal) and were plated at limiting dilution. Individual clones
were picked and analyzed for high CD4 expression. One clone that
expressed uniformly high levels of CD4 was arbitrarily chosen and named
MGT5 for murine/GFP/T4/CCR5. MGT5 cells were infected with the
hu-cyclin T1 retroviral expression vector pBABE.cyT(hygro) based on the
retroviral vector pBABE.hygro (36). The infected cells were
selected in medium containing 200 µg of hygromycin per ml. Individual
drug-resistant clones were expanded and analyzed for their response to
transfected Tat expression vector. A clone was chosen and named
MGT5.cyT for murine/GFP/T4/CCR5/cyclin T1.
GHOST.R5 (provided by V. KewalRamani and D. Littman) is a reporter cell
line based on the human osteosarcoma cell line HOS. These cells contain
a transactivatable HIV-2 LTR-EGFP cassette and express hu-CD4 and
hu-CCR5 (24).
CEM.CCR5.GFP reporter cells were derived by electroporating CEMx174
cells with pLTR-EGFP and selecting for G418 resistance. Resistant cells
were cloned by limiting dilution and then screened by FACS for those
with low constitutive green fluorescence and high-level induction of
GFP fluorescence following HIV-1 infection. These were used for
end-point dilution titer determination of viruses produced from the
infected murine cells.
Viruses and infections.
NL4-3(VSV-G) replication-competent
pseudotypes were produced by transfecting 293T cells with an equal
amount of pNL4-3 and VSV-G expression vector. Culture supernatants were
harvested 48 h postinfection, filtered, and frozen at
80°C in
aliquots. Luciferase reporter viruses were produced by cotransfecting
293T cells with NL-Luc-E
R
and Env
expression vectors for JR.FL or VSV-G as previously described (12). For dual luciferase infections, the NL-Luc
R
E
vector (10) was modified by
replacing the firefly luciferase gene with that Renilla
luciferase gene (Promega). Cultures were infected with an equal mixture
of the two different reporter viruses, and each virus was quantitated
independently using dual luciferase reporter assay reagents (Promega).
Viruses were quantitated by p24gag enzyme-linked
immunosorbent assay (ELISA).
M-tropic, replication-competent HIV-1 isolates JR.FL and MJM were
expanded on phytohemagglutinin-activated human peripheral blood
mononuclear cells and then amplified on HOS.CD4.CCR5 cells. MJM is a
rapidly replicating CCR5-dependent patient isolate (provided by R. Connor, Aaron Diamond AIDS Research Center). OM10.1 cells are
derivatives of the promyelocytic cell line HL-60, which harbors a
latent HIV-1 provirus that can be induced by tumor necrosis factor
alpha (TNF-
) (9).
Quantitative-competitive PCR quantitation of proviral copy
number.
Genomic DNA was prepared from 106 murine and
106 human cells 3 days postinfection and then cleaved with
SphI to decrease its viscosity. Aliquots of genomic DNA (1 µg) were mixed with decreasing quantities of competitor pNL4-3
containing a 1.4-kb deletion in env from the NheI
to HpaI sites (nucleotides [nt] 6628 to 8028). The mixture
was amplified by PCR using primers RC-9 and RC-12 (11),
which flank env. Amplified proviral and competitor plasmid were separated by electrophoresis through 1% agarose, visualized by
ethidium bromide staining, and quantitated by densitometry.
Northern blotting.
Total cellular RNA was isolated from
cells infected 3 days earlier with NL4-3(VSV-G) using Triazol (Life
Technologies). RNA (10 µg) was separated by electrophoresis on an
agarose-formaldehyde gel and transferred to a nylon filter. The filter
was hybridized to an [
-32P]dCTP-labeled HIV-1 LTR
probe derived from the XhoI-BglII fragment (nt
8265 to 8419) of HIV-1SF2. The filters were exposed to film and subsequently quantitated using a PhosphorImager and ImageQuant software (Molecular Dynamics). The filter was then stripped and reprobed with an antisense oligonucleotide to glyceraldehyde phosphate dehydrogenase mRNA (nt 1017 to 1037).
Western blotting.
Cells were infected with NL4-3(VSV-G), and
3 days later virions and cell lysates were prepared. Virions were
pelleted by centrifuging 10 ml of filtered culture supernatant at
35,000 rpm in an SW40Ti rotor for 1 h and lysed in lysis buffer
(100 mM NaCl, 10 mM EDTA, 20 mM Tris [pH 7.5], 1% Triton X-100, 1%
sodium deoxycholate). Cell lysates were prepared by removing medium
from the infected cells, washing them with phosphate-buffered saline,
and lysing them in 500 µl of lysis buffer. Protein in the lysates was
quantitated by using Coomassie blue reagent (Bio-Rad) and stored at
80°C before use. Lysate containing 10 µg of protein was separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
transferred to polyvinylidene difluoride filters, and probed with serum
from an AIDS patient (1:500 dilution; gift of D. Richman, University of
California San Diego) followed by horseradish peroxidase-conjugated rabbit anti-human antibody (BioSource International). Filters were
developed using luminescent enhanced chemiluminescence reagents (Amersham) and quantitated by using a PhosphorImager.
Density gradient centrifugation of virions.
Supernatants (3 ml) from murine and human cells that had been infected 3 days earlier
at high multiplicity of infection (MOI) with NL4-3(VSV-G) were overlaid
on 20 to 60% linear sucrose gradients. The gradients were centrifuged
at 35,000 rpm in an SW40T: for 12 h and fractionated into 10, 0.9-ml fractions. The density of each fraction was determined by
refractometry. The fractions were then diluted with 2 volumes of TNE
(10 mM Tris [pH 7.5], 100 mM NaCl, 1 mM EDTA) and centrifuged for
1 h at 35,000 rpm in an SW55Ti rotor. Pelleted virions were
resuspended in 100 µl of lysis buffer. p24gag
was quantitated in the fractions by ELISA.
Electron microscopy.
MGT5 and MGT5.cyT cells were seeded on
large glass coverslips in 10-cm dishes (106 per dish) and 1 day later were infected with NL4-3(VSV-G) at a MOI of 0.5. The cells
were fixed 72 h postinfection in situ for 20 min with cold 2.5%
glutaraldehyde in 100 mM PIPES (piperazine-1,4-bis-2-ethanesulfonic acid [pH 6.9]). Fixed cells were scraped from the coverslip with a
rubber policeman, collected by low-speed centrifugation at 4°C, washed three times in cold 100 mM PIPES, and postfixed in 1% osmium tetroxide in PIPES for 30 min at 4°C. After extensive washing in 100 mM PIPES, the cells were embedded in low-melting-temperature agarose
(Sigma) and further treated with 1% tannic acid for 10 min. Finally,
agar blocks were dehydrated in ethanol and embedded in ERL resin.
Silver-gray sections were stained with lead citrate and uranyl acetate.
The sections were examined in a Philips CM120 electron microscope at 60 kV.
 |
RESULTS |
Expression of hu-CD4, hu-CCR5, and hu-cyclin T1 in murine cells
allows for HIV-1 infection but not replication.
To analyze the
blocks to HIV-1 replication in murine cells, we derived reporter cell
lines MGT5 and MGT5.cyT, based on NIH 3T3 fibroblasts (Fig.
1A). MGT5 was established by first
introducing an HIV-1 LTR-EGFP cassette into NIH 3T3 cells and then
transducing hu-CCR5 and hu-CD4 with retroviral vectors. Individual cell
clones were evaluated by flow cytometry, and a clone with low-level
constitutive green fluorescence and uniform CCR5 and CD4 expression was
chosen. hu-cyclin T1 was introduced into MGT5 by retroviral vector
transduction, resulting in MGT5.cyT. These cells are the murine
equivalents of GHOST.R5 (24), a HOS-derived cell line that
expresses CD4 and CCR5 and contains LTR-EGFP. The murine cell lines
expressed cell surface CD4 at levels approximating those of GHOST.R5
(Fig. 1B). hu-CCR5 was expressed at a slightly higher level in MGT5.cyT than in MGT5, possibly due to a transcriptional effect of cyclin T1.
Expression of cyclin T1 could not be directly quantitated in these
cells because of the presence of the endogenous murine cyclin T1, but
it was verified by Western analysis in NIH 3T3 cells expressing
HA-tagged cyclin T1 in cells prepared in parallel (data not shown).
Although fibroblasts are not natural targets of HIV-1 in vivo, NIH 3T3
cells support HIV-1 reverse transcription and integration (28,
40) and, when transfected with hu-CD4 and CCR5 or CXCR4, support
entry (3). In contrast, lymphoid cells from hu-CD4/CXCR4
transgenic mice were poorly infectable by reporter virus (data not
shown). Moreover, human fibroblastic cell lines, such as HOS.CD4.CCR5
or HeLa.CD4, are highly permissive for HIV-1 replication, indicating
the ability of HIV-1 to replicate efficiently in nonlymphoid cells once
the entry block is removed.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Derivation of MGT5 and MGT5.cyT reporter cells. (A) NIH
3T3 cells were transfected with pLTR.EGFP, which contains the HIV-1 LTR
linked to the EGFP gene. hu-CD4, hu-CCR5, and hu-cyclin T1 were
introduced using pBABE retroviral vectors (36). MGT5.cyT was
transduced with BABE.CyT.hygro; MGT5 contains control vector
BABE.hygro. (B) FACS analysis of CCR5 and CD4 on MGT5, MGT5.cyT,
GHOST.R5, and NIH 3T3 cells.
|
|
To determine whether hu-cyclin T1 would restore high-level expression
of integrated HIV-1 provirus in murine cells, MGT5 and MGT5.cyT were
infected with NL4-3 (VSV-G). This virus has a higher infectivity than
wild-type HIV-1 and was therefore used to achieve high levels of
infection in the murine cells in the absence of virus replication. In
addition, because NL4-3 requires CXCR4 and cannot use CCR5, the
NL4-3(VSV-G) pseudotype was restricted to a single round of replication
in the GHOST.R5 cells. This allowed a comparison between the human cell
line and the murine cell line, which supports only a single round of
virus replication (as shown below). At 2 days postinfection, the
majority of MGT5.cyT and GHOST.R5 cells were brightly fluorescent (Fig.
2A).
Fluorescent cells were not observed in
the infected MGT5 culture.


View larger version (2332K):
[in this window]
[in a new window]
|
FIG. 2.
Cyclin T1 restores HIV expression but not replication in
the murine cell line. (A) Murine and human cell lines were infected
with 25 ng of p24gag NL4-3(VSV-G) and
photographed under UV light 48 h later. Uninfected cells are shown
below. (B) Murine and human cells were infected with the amounts of
NL4-3(VSV-G) p24gag indicated on the right. The
percentage of cells within the gate defined by the vertical line in
each panel is indicated. (C) MGT5, MGT5.cyT, and GHOST.R5 cells were
infected with M-tropic HIV-1 isolates JR.FL and MJM at an MOI of 0.05, and p24gag production was measured for 14 days.
Continuation of the cultures for up to 4 weeks did not result in virus
production from the murine cells (data not shown).
FIG.2 Continued.
|
|
Quantitation of the number of fluorescent cells and their intensity by
flow cytometry showed that the GHOST.R5 and MGT5.cyT cells were
infected to a similar extent over a range of input virus levels (Fig.
2B). MGT5 had considerably fewer fluorescent cells, although they
contained equivalent numbers of HIV-1 proviruses, as shown below. The
fluorescence intensity of the MGT5.cyT was considerably higher than
that of MGT5 but was still two- to threefold lower than that of
GHOST.R5. Thus, cyclin T1 largely, but not completely, restored the
deficiency in the ability of the murine cell to activate the HIV-1 LTR.
Expression of the three human cofactors, however, was not sufficient to
cause the murine cells to become permissive for HIV-1-replication. Infection of the three cell lines with the M-tropic HIV-1 isolates MJM
and JR.FL did not result in production of detectable amounts of
supernatant p24gag over a 2-week period (Fig.
2C). Thus, HIV-1 replication was blocked in the murine cells at a
postentry, posttranscription stage of virus replication.
Efficient HIV DNA synthesis and integration in the murine
cells.
To evaluate the ability of the murine cells to support
HIV-1 DNA synthesis and integration, viral DNA in the infected murine and human cells was measured by quantitative-competitive PCR. Latently
infected OM10.1 cells that harbor a single HIV-1 provirus were
used for standardization. GHOST.R5 cells contained a proviral load
similar to that of OM10.1. The MGT5 and MGT5.cyT provirus loads were
about twofold lower (Fig. 3). It was not
clear whether the slightly increased amount of virus DNA in the
GHOST.R5 cells was due to a small increase in DNA synthesis or to
experimental variability. Although the GHOST.R5 cells contained more
viral DNA than the murine cells, they did not show a correspondingly greater proportion of fluorescent cells. This could indicate that the
murine cells expressing hu-cyclin T1 are more efficient at activating
the integrated LTR-EGFP than are the human cells. GHOST.R5 contains an
HIV-2 LTR-EGFP, which may be less responsive to HIV-1 Tat than is the
HIV-1 LTR-EGFP in MGT5 cyT. In this analysis, the DNA measured is
likely to represent integrated provirus, since unintegrated forms tend
to be rapidly lost (41), although some contribution of
unintegrated circles cannot be excluded. Taken together, these data
suggest that the murine cells support reverse transcription and
integration with an efficiency similar to that of highly permissive
human cells and that cyclin T1 affected proviral expression but not any
other early steps in virus replication.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Murine cells support efficient HIV-1 provirus formation.
Cells were infected with NL4-3(VSV-G) at an MOI of 1. Genomic DNA was
prepared 2 days later, and proviral copy numbers were determined by
quantitative-competitive PCR. Competitor DNA deleted between the
NheI and HpaI sites flanking env was
added in the amounts indicated above each lane. DNA from OM10.1 cells
containing a single provirus per cell was used for calibration. The
proviral load per cell calculated from band intensities normalized to
OM10.1 was as follows: GHOST.R5 = 1, MGT5 = 0.5, and
MGT5.cyT = 0.25.
|
|
Murine cells synthesize and splice HIV-1 RNA.
In
HIV-1-infected cells, the quantity of HIV-1 mRNA is controlled by the
LTR and by Tat while the characteristic pattern of fully spliced,
partially spliced, and unspliced viral mRNA transcripts is regulated by
Rev (reviewed in reference 42). While the intensity of EGFP fluorescence in the infected MGT5.cyT cells suggested that
HIV-1 RNA had been synthesized, this was not indicative of Rev
activity, since the LTR-EGFP was activated by Tat, which is synthesized
from a Rev-independent, fully spliced transcript. To evaluate the
production of HIV-1 mRNA transcripts in murine cells, HIV-1 transcripts
in the NL4-3(VSV-G)-infected cells were visualized by Northern
blotting. At 3 days postinfection, the murine MGT5.cyT cells were found
to contain the characteristic unspliced, singly spliced, and multiply
spliced mRNA transcripts (Fig. 4),
although at a slightly altered ratio. The proportion of the unspliced
transcript was somewhat reduced compared to that in the human cells
(unspliced/multiply spliced ratio of 11.4 in GHOST.R5 and 5.0 in
MGT5.cyT), and the relative amount of unspliced transcript was about
threefold lower in the murine cells. Real-time PCR quantitation of
these transcripts confirmed these results (data not shown). Thus, Rev
function was intact in the murine cells. The reduction in unspliced
transcript could have been due to a small reduction in Rev activity in
the murine cells or to more rapid degradation of the long transcript.
Transfecting an expression vector for the Rev cofactor Crm-1/exportin-1
(42) did not alter the ratio of transcripts in the murine
cells (data not shown). In addition, while the human cells produced
threefold more HIV-1 mRNA transcripts than did the murine cells, they
contained two- to fourfold more proviruses. Thus, on a per provirus
basis, the murine cells produced mRNA transcripts at a level comparable to that of the human cells.

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 4.
Murine cells produce unspliced and spliced HIV-1
transcripts. Murine and human cells (2 × 106) were
infected with NL4-3(VSV-G) at an MOI of 1. At 2 days postinfection,
total RNA was prepared and HIV RNA transcripts were detected by
Northern blotting using an LTR probe. Unspliced (US), singly spliced
(SS), and multiply spliced (MS) transcripts are indicated by arrows.
The filter was reprobed with a glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) probe to control for equal RNA loading. The ratio of unspliced
to multiply spliced transcripts was 11.4 for GHOST.R5 and 5.0 for
MGT5.cyT; the ratio of intensities of the unspliced transcript GHOST.R5
compared to MGT5.cyT was 3.0 and for multiply spliced it was 1.3, as
determined by PhosphorImager analysis.
|
|
Murine cells synthesize and process HIV-1 proteins but fail to
release virions efficiently.
Production of viral proteins by the
NL4-3(VSV-G)-infected murine and human cell lines was evaluated by
Western analysis of cell lysates and supernatants. This analysis showed
that the infected GHOST.R5 and MGT5.cyT cells contained readily
detectable amounts of HIV-1 structural proteins (Fig.
5). Lysates of GHOST.R5 and MGT5.cyT contained Gag polyproteins
pr55gag and pr160gag/pol,
the Gag-processing intermediate pr41, and fully processed Gag proteins p24 CA and p17 MA. The presence of
pr160gag/pol at an abundance similar to that of
GHOST.R5 suggested that the translational frameshifting event required
for synthesis of the Gag-Pol polyprotein occurred in the murine cells
at a frequency comparable to that in human cells, consistent with an
earlier report by Moosmayer et al. (35). Importantly, while
the pr55gag polyprotein was present at a similar
abundance in the murine and human cells, fully processed CA was
significantly reduced in abundance in the murine cells. Quantitation of
the band intensities showed that pr55gag was
actually present at slightly higher level in the MGT5.cyT than in the
GHOST.R5 cells but that CA was reduced 7.7-fold in the murine cells
(Table 1). In GHOST.R5, CA was about 46%
as abundant as pr55gag, while in MGT5.cyT, CA
was about 5% as abundant.

View larger version (80K):
[in this window]
[in a new window]
|
FIG. 5.
HIV-1-infected murine cells synthesize viral proteins
but fail to efficiently release virions. Murine and human cells were
infected with NL4-3(VSV-G) at an MOI of 1. At 3 days later, virions
were pelleted from the culture medium and cell lysates were prepared.
Viral proteins in the virions and cell lysates were visualized on a
Western blot probed with patient serum. For the lysates, a fixed amount
of protein from the murine cells and 10-fold-decreasing amounts of
protein starting at 5 µg from the human cells was loaded. For the
virions, amounts corresponding to 1.0 or 0.1 ml were loaded, as
indicated above the lanes.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Quantitation of band intensities derived from Western
analysis of virion structural proteins in infected cell lysates
|
|
While virion polyprotein precursor proteins were present at similar
abundance in the murine and human cells, the amount of virion protein
that could be pelleted from culture supernatants of infected MGT5.cyT
cells was dramatically reduced (Fig. 5). This could not be explained by
the disintegration of the murine released virions into nonpelletable
subunits, because p24gag measurement of
supernatants without centrifugation showed that they contained less
than 1/500 as much p24gag (see Fig. 7B). Thus,
the murine cells failed to secrete virions efficiently.
It was possible that the block to virus assembly and secretion in the
murine cells was due to failure of the cells to produce a sufficient
quantity of virion structural proteins. This could have been the case
if virus assembly required a threshold concentration for aggregation
and condensation of the virion. To test whether this was the case, we
analyzed virion production in the latently infected human cell line
OM10.1, in which virus expression can be controlled by TNF-
(9). OM10.1 cells were exposed to decreasing concentrations
of the inducer TNF
. Viral proteins were then visualized by Western
analysis and quantitated by p24gag ELISA. This
showed that by decreasing the concentrations of TNF-
, it was
possible to titrate viral protein production down to low levels (Fig.
6). As the amount of viral protein in the
cell lysates decreased, the ratio of unprocessed to processed Gag
remained similar. This suggested that virions were able to assemble
even with a very low abundance of precursor proteins, an abundance considerably lower than that of the infected MGT5.cyT cells (Fig. 6A,
top panel). Moreover, the human cells efficiently released small
quantities of virions in response to low doses of TNF-
(Fig. 6A,
bottom panel). This was evident by Western analysis of the virions and
by the consistency of p24gag levels in the
supernatant and lysates in response to decreasing levels of TNF-
stimulation (Fig. 6B). Taken together, these data suggest that HIV-1
assembly is efficient in human cells even in the presence of only low
levels of virion protein. Thus, the murine cells appear to have a
specific defect in their ability to assemble virions.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Infected murine cells contain Gag at levels sufficient
to allow virion assembly. (A) OM10.1 cells were treated with 5.0, 1.0, 0.2, 0.02, 0.01, 0.005, or 0 U of TNF- per ml in the lanes below the
triangle. GHOST.R5 and MGT5.cyT were infected with NL4-3(VSV-G), and
lysates and virions from each culture were prepared 3 days later. Viral
proteins were analyzed on Western blots with AIDS patient serum. (B)
p24gag concentration in lysates and virions.
|
|
Murine cells produce small numbers of infectious virions.
Although the murine cells released only small amounts of
p24gag, it remained possible that this was in
the form of infectious virions. To test whether the
p24gag had been released from the cells in the
form of virions, supernatants from NL4-3(VSV-G)-infected MGT5.cyT cells
were subjected to sucrose density gradient analysis (Fig.
7A). Supernatant, without pelleting, was
layered on a sucrose density gradient and centrifuged to equilibrium. Analysis of gradient fractions showed that
p24gag banded at 1.14 g/ml, a density consistent
with that of virions and similar to the density of virions produced by
the human cell line 293T. Similar results were obtained with GHOST.R5
cells, but these were less efficient at producing virions than were the 293T cells (data not shown). A high-density peak was present in the
293T-derived gradient, possibly corresponding to aberrantly formed
virions secreted by these cells.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 7.
Murine cells produce infectious virus. (A) Murine and
human cells were infected with NL4-3(VSV-G). At 3 days postinfection,
the density of virions in the supernatant was measured by sucrose
density gradient centrifugation. (B) p24gag was
quantitated in cell lysates and from pelleted virions. (C) The
infectious titer (TCID50) of supernatant virus was measured
by end-point dilution on CEM.LTR.GFP cells. The ratio of
TCID50 to supernatant p24gag is 154 and 236 for the MGT5.cyT- and GHOST.R5-produced viruses,
respectively.
|
|
Infectivity of the mouse cell-produced virus was determined by
end-point dilution analysis. This showed that the MGT5.cyT cells
produced a low but significant titer of infectious virus, a finding
that was reproducible over three repetitions of the experiment (Fig.
7B). This finding was not due to carryover of input virus, since the
MGT5-derived supernatant never showed any measurable titer in the
limiting-dilution assay. The 50% tissue culture infective dose
(TCID50) for the mouse cell-derived virus was about 35-fold
lower than that derived from the human cell line, but when normalized
for p24gag it had an infectivity only marginally
reduced from that of the human cell line-derived virus. Thus, there is
no absolute block to HIV-1 replication in the murine cell line; the
virus that buds from the mouse cells is as infectious as that from
human cells.
Aberrant structures accumulate in vesicles.
Electron
microscopic analysis of the infected MGT5.cyT cells showed rare,
budding structures at the plasma membrane that were of normal size and
morphology (Fig. 8C). Such structures
were not observed in infected MGT5 cells or uninfected controls. A few
extracellular immature (Fig. 8D) and mature (Fig. 8E) particles were
detected near the plasma membrane of infected MGT5.cyT cells but not in
uninfected or MGT5 cells. The virions were of typical size and
appearance, and the characteristic cone-shaped internal core structure
of mature HIV-1 virions was apparent in a small number of instances
(Fig. 8E). No budding structures at intracellular membranes and no
cytoplasmic or vesicle-associated capsids or virus-like particles were
observed.

View larger version (179K):
[in this window]
[in a new window]
|
FIG. 8.
Ultrathin-section electron microscopic analysis of
infected MGT5.cyT cells. (A) Overview of an infected MGT5.cyT cell. (B)
Detail of an infected cell, revealing a complex vesicular
cytoarchitecture. Note the thickened contrast-rich membranes situated
in close association with cisternae of the endoplasmic reticulum
(arrowheads). Adjacent is a dense body (D), also surrounded by a
thickened membrane. (C to E) Budding structures and immature and mature
HIV-1 particles, respectively.
|
|
While the cellular architecture was well preserved, large numbers of
electron-dense structures were present in the cytoplasm of the infected
MGT5.cyT cells but not in uninfected control cells. These structures
often appeared as multivesicular bodies or multicentric myelin figures
characteristic of lamellar lysosomes (Fig. 8A). Lamellar lysosomes and
vesicular primary lysosomes were sometimes joined, segregating portions
of the cytoplasm containing the dense material (Fig. 8A). In addition,
infected but not uninfected MGT5.cyT cells frequently exhibited
contrast-rich membranes associated with the lysosomal complexes (Fig.
8B). These structures correspond to thick electron-dense layers, which
were often close to but clearly separated from cisternae of the
endoplasmic reticulum (Fig. 8B). Similar structures were also detected
in infected MGT5 cells but at a much lower frequency (data not shown).
Assuming that the electron-dense material was viral Gag precursor
protein, these observations suggest that virion proteins had not been
targeted correctly to the cell membrane but had been inappropriately
targeted to vesicles.
CCR5 and CD4 on the murine cells mediate entry with reduced
efficiency.
In the experiments described above, VSV-G pseudotypes
that bypass CD4/coreceptor-mediated entry were used to achieve
efficient infection. To evaluate the efficiency of
CD4/coreceptor-mediated entry in the murine cells, MGT5.cyT and
GHOST.R5 cells were infected with a mixture of two luciferase reporter
viruses: CCR5-specific JR.FL pseudotyped firefly luciferase reporter
virus and VSV-G pseudotyped Renilla firefly reporter virus
(in which the firefly reporter gene was replaced by Renilla
luciferase). This procedure allowed the measurement of both viruses in
dually infected cultures, permitting normalization for any postentry
differences between the cell types. In GHOST.R5 cells, the JR.FL
pseudotype induced luciferase activity close to (about 75%) that of
the VSV-G pseudotype (Fig. 9A). In
MGT5.cyT cells, JR.FL entry was less efficient than that of VSV-G
(about 20%). This difference was not due to postentry differences
between the two cell lines, since the VSV-G pseudotype was used to
normalize for such differences. Nor was the difference due to limiting
amounts of CD4 or CCR5, since these were expressed in ample amounts in
the murine cells, as shown above (Fig. 1B). Thus, hu-CD4/hu-CCR5 on the
murine cells mediated HIV-1 entry but at significantly reduced
efficiency with JR.FL Env.


View larger version (25113K):
[in this window]
[in a new window]
|
FIG. 9.
Efficient syncytium formation but decreased
coreceptor-mediated entry in the murine cell line. (A) The murine and
human cells were infected with a mixture of JR.FL pseudotype containing
a firefly luciferase reporter gene and VSV-G pseudotype containing
Renilla luciferase reporter gene. The activities of the two
luciferase enzymes were quantitated using reagents discriminating
between the two enzymes. Data are reported as the ratio of JR.FL- to
VSV-G-mediated infection (firefly divided by Renilla
luciferase activity in counts per second). (B) Syncytium formation
assay in which 293T cells expressing transfected JR.FL Env were
cocultured for 18 h with MGT5 or GHOST.R5. Representative fields
are shown.
|
|
The reduced amount of hu-CD4/hu-CCR5-mediated entry in the murine cells
was not due to an inability of the murine cells to support Env-mediated
fusion. This was shown in a syncytium formation assay in which 293T
cells transiently expressing a transfected Env expression vector were
cocultured with the murine human cell lines (Fig. 9B). MGT5.cyT cells
formed large multinucleated syncytia, consistent with earlier findings
(3), and these were more pronounced than in the GHOST.R5
cells. Syncytia were not formed in control cocultures (Fig. 9B). These
findings suggested that reduced entry into the murine cells was not due
to inefficiency of the fusion reaction in the MGT5.cyT cells but
perhaps was due to some other, less well understood activity of
hu-CD4/hu-CCR5 during entry.
 |
DISCUSSION |
Murine NIH 3T3 fibroblasts stably expressing hu-CD4, hu-CCR5, and
hu-cyclin T1 fail to support HIV-1 replication primarily because of a
block to virus assembly. Interestingly, the cells supported the other
steps of the HIV-1 replication cycle. Reverse transcription/integration, proviral transcription, protein synthesis, and frameshifting were nearly as efficient as in human cells, while
production of unspliced HIV-1 mRNA transcripts and CD4/CCR5-mediated virus entry were somewhat reduced. In contrast, the block to virus assembly was dramatic. Upon infection with NL4-3(VSV-G) pseudotypes, the murine cells produced large amounts of Gag and Gag-Pol, but this
accumulated in the cells in vesicular structures and was largely not
released. The Gag proteins were inefficiently processed by the viral
protease, probably as a result of their failure to assemble, consistent
with earlier findings in transfected rodent cells (35).
Importantly, the infected murine cells produced small amounts of
virions, and these were as infectious on a per-particle basis as those
from human cells, consistent with findings by Garber et al.
(18), who used transfected NIH 3T3 cells.
Provirus expression, which is nearly undetectable in NIH 3T3 cells, was
largely restored by expressing hu-cyclin T1, consistent with earlier
findings (18). The small reduction in LTR-EGFP activation in
the infected MGT5.cyT cells could have been caused by competition from
the endogenous mu-cyclin T1, which is thought to have dominant negative
activity on the human protein (6, 27), or to inefficient LTR
function resulting from incompatibilities between murine transcription
factors and LTR binding-site sequences. We could not distinguish
between these two possibilities. Decreased Tat activity does not appear
to account for the failure of the virus to replicate in MGT5.cyT cells,
since upon infection, the cells produced ample amounts of virion
structural proteins.
An earlier report (49) suggested that there is a block to
Rev function in murine cells; however, this did not appear to be the
case in our study. Judging by the ratio of spliced to unspliced HIV-1
mRNA transcripts and indirectly by the accumulation of viral structural
proteins which are translated from Rev-dependent mRNA transcripts, Rev
function was largely intact in the murine cells. A threefold reduction
in the relative abundance of the unspliced transcript in the murine
cells was noted, perhaps reflecting a small reduction in Rev activity;
however, this could also be caused by some instability of the unspliced
transcript, which, because of its failure to be encapsidated by
assembling virions, may be more rapidly degraded by cellular RNase.
Transfecting the murine cells with Crm-1/exportin-1 expression vector,
the human Rev cofactor (42), did not alter viral protein
production or mRNA transcript ratios (data not shown).
While some steps of the virus replication cycle were somewhat less
efficient in the murine cell line (mRNA synthesis and virus entry), the
block to assembly was drastic. Although the murine cells contained
amounts of Gag polyprotein at levels comparable to that in the human
cells, the levels of p24gag released were more
than 500-fold reduced. The reason for the failure to assemble virions
is unknown. Processing of the Gag polyprotein by the viral protease was
inefficient; however, this was more likely to have been a consequence
of the failure of the polyprotein molecules to assemble than its cause,
since processing is not required for budding (16). In
addition, it was not likely to have been due to a failure to
incorporate cyclophilin, since incorporation of this cellular protein
is not required for assembly or budding (53). Nor was it due
to an inappropriate association of Env with Gag at the cell membrane,
since cells infected with Env
NL4-3(VSV-G) also failed to
assemble virions (data not shown).
The inability of the murine cells to support HIV-1 assembly is
presumably caused either by the absence of a required human-specific host factor or by the presence of an inhibitory murine factor. HIV-1
assembles at the cell membrane by a process similar to that of the type
C retroviruses (16). The Gag polyproteins are transported to
the cell membrane in an energy-dependent process (31) that may be mediated by vesicles (22, 25) and that is directed by
specific domains of MA. MA contains an N-terminal basic patch and an
N-terminal myristate that are required for membrane attachment (16, 46, 54). Deleting a portion of MA results in targeting of viral assembly to intracellular membranes (14). Adding a src membrane-targeting sequence to an intracisternal A-type
particle Gag redirected it to assemble at the cell membrane, release,
and process (52). In the infected murine cells,
inappropriate targeting of the Gag polyprotein could have caused the
accumulation of virion proteins in vesicular structures that we
observed by electron microscopy. Targeting to the cell membrane could
involve cellular cofactors, such as those that mediate protein folding
or intracellular transport, any of which could be altered or lacking in
the murine cells. Using an in vitro assembly system, Lingappa et al.
(31) detected at least two host cofactors, one detergent
sensitive and the other insensitive, that were required for the
assembly of HIV-1 capsids. Whether these activities are present in
murine cells is not known. In addition, the chaperonin T-complex
polypeptide has been implicated as playing a role in hepatitis B virus
assembly (32). A similar factor could play a role in HIV-1 assembly.
Alternatively, murine cells might contain an inhibitor of virus
assembly. The expression of variant HIV-1 Gag molecules in human cells
interferes with the production of infectious particles (50).
By analogy, endogenous murine retroviral Gag proteins or fortuitous
interaction of the Gag polyprotein with murine cellular proteins could
interfere with assembly. Because the virus has evolved to replicate in
human cells, it would not have been selected to avoid interference by
murine cellular proteins. Our data do not allow us to distinguish
between the two types of models; however, supporting the former
hypothesis, Trono and Baltimore found that fusing a human cell line to
HIV-1-infected NIH 3T3 cells boosted the release of
p24gag (49).
The finding that the murine cells produced virions with an infectivity
similar to that of virions from human cells indicates that there is no
absolute block to HIV-1 replication in murine cells. The failure to
support replication probably results from the combination of
insufficient numbers of infectious particles released and decreased
entry efficiency. Conceivably, long-term adaptation of the virus to
growth in murine cells could select for a rapidly growing variant;
however, this did not occur following culturing of MGT5.cyT with
replication-competent M-tropic HIV-1 for more than 4 weeks (data not
shown). Establishing a murine model for HIV-1 replication will require
more extensive alteration to the virus than that which occurs during
virus replication or will require identification of the factors that
mediate HIV-1 assembly.
 |
ACKNOWLEDGMENTS |
We thank Jason McInerney, Klaus Wiegers, Michael Craig, and
Stephanie Maifert for technical assistance; Sharon Lewin for real-time PCR analysis; and Douglas Richman, Richard Kornbluth, Katherine Jones,
Mark Muesing, Vineet KewalRamani, Dan Littman, and Ruth Connor for
donating reagents.
The work was funded by NIH grants AI43252 and CA7214, Elisabeth Glaser
Pediatric AIDS Foundation grant 77328 to R.M., J. B. Pendelton Trust,
and the National Institute of Standards and Technology Advanced
Technology Program (grant 97-01-0240 to Maxygen Inc., Redwood City,
Calif.). N.R.L. is an Elizabeth Glaser Scientist of the Elizabeth
Glaser Pediatric AIDS Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Infectious
Disease Laboratory, The Salk Institute for Biological Studies, 10010 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (858) 453-4100. Fax: (858)
554-0341. E-mail: Landau{at}salk.edu.
 |
REFERENCES |
| 1.
|
Alonso, A.,
D. Derse, and B. M. Peterlin.
1992.
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
J. Virol.
66:4617-4621[Abstract/Free Full Text].
|
| 2.
|
Atchison, R. E.,
J. Gosling,
F. S. Monteclaro,
C. Franci,
L. Digilio,
I. F. Charo, and M. A. Goldsmith.
1996.
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.
Science
274:1924-1926[Abstract/Free Full Text].
|
| 3.
|
Berger, E. A.
1997.
HIV entry and tropism: the chemokine receptor connection.
AIDS
11(Suppl. A):S3-S16.
|
| 4.
|
Berger, E. A.,
P. M. Murphy, and J. M. Farber.
1999.
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Annu. Rev. Immunol.
17:657-700[CrossRef][Medline].
|
| 5.
|
Bieniasz, P. D.,
R. A. Fridell,
K. Anthony, and B. R. Cullen.
1997.
Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1.
J. Virol.
71:7097-7100[Abstract].
|
| 6.
|
Bieniasz, P. D.,
T. A. Grdina,
H. P. Bogerd, and B. R. Cullen.
1999.
Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes.
J. Virol.
73:5777-5786[Abstract/Free Full Text].
|
| 7.
|
Bieniasz, P. D.,
T. A. Grdina,
H. P. Bogerd, and B. R. Cullen.
1998.
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.
EMBO J.
17:7056-7065[CrossRef][Medline].
|
| 8.
|
Browning, J.,
J. W. Horner,
M. Pettoello-Mantovani,
C. Raker,
S. Yurasov,
R. A. DePinho, and H. Goldstein.
1997.
Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection.
Proc. Natl. Acad. Sci. USA
94:14637-14641[Abstract/Free Full Text].
|
| 9.
|
Butera, S. T.,
V. L. Perez,
B. Y. Wu,
G. J. Nabel, and T. M. Folks.
1991.
Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection.
J. Virol.
65:4645-4653[Abstract/Free Full Text].
|
| 10.
|
Connor, R. I.,
B. K. Chen,
S. Choe, and N. R. Landau.
1995.
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Virology
206:936-944.
|
| 11.
|
Connor, R. I.,
K. E. Sheridan,
C. Lai,
L. Zhang, and D. D. Ho.
1996.
Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.
J. Virol.
70:5306-5311[Abstract/Free Full Text].
|
| 12.
|
Deng, D.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. DiMarzio,
S. Marmon,
R. E. Sutton,
C. M. Hill,
C. B. Davis,
S. C. Peiper,
T. J. Schall,
D. R. Littman, and N. R. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[CrossRef][Medline].
|
| 13.
|
Dunn, C. S.,
M. Mehtali,
L. M. Houdebine,
J. P. Gut,
A. Kirn, and A. M. Aubertin.
1995.
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits.
J. Gen. Virol.
76:1327-1336[Abstract/Free Full Text].
|
| 14.
|
Fäcke, M.,
A. Janetzko,
R. L. Shoeman, and H. G. Kräusslich.
1993.
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.
J. Virol.
67:4972-4980[Abstract/Free Full Text].
|
| 15.
|
Filice, G.,
P. M. Cereda, and O. E. Varnier.
1988.
Infection of rabbits with human immunodeficiency virus.
Nature
335:366-369[CrossRef][Medline].
|
| 16.
|
Freed, E. O.
1998.
HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology
251:1-15[CrossRef][Medline].
|
| 17.
|
Garber, M. E., and K. A. Jones.
1999.
HIV-1 Tat: coping with negative elongation factors.
Curr. Opin. Immunol.
11:460-465[CrossRef][Medline].
|
| 18.
|
Garber, M. E.,
P. Wei,
V. N. KewalRamani,
T. P. Mayall,
C. H. Herrmann,
A. P. Rice,
D. R. Littman, and K. A. Jones.
1998.
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.
Genes Dev.
12:3512-3527[Abstract/Free Full Text].
|
| 19.
|
Gold, M.,
X. Yang,
C. Herrmann, and A. Rice.
1997.
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.
J. Virol.
72:4448-4453[Abstract/Free Full Text].
|
| 20.
|
Gordon, M. R.,
M. E. Truckenmiller,
D. P. Recker,
D. R. Dickerson,
E. Kuta,
H. Kulaga, and T. J. Kindt.
1990.
Evidence for HIV-1 infection in rabbits. A possible model for AIDS.
Ann. N.Y. Acad. Sci.
616:270-280[CrossRef][Medline].
|
| 21.
|
Hanna, Z.,
D. G. Kay,
N. Rebai,
A. Guimond,
S. Jothy, and P. Jolicoeur.
1998.
Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.
Cell
95:163-175[CrossRef][Medline].
|
| 22.
|
Hansen, M.,
L. Jelinek,
S. Whiting, and E. Barklis.
1990.
Transport and assembly of gag proteins into Moloney murine leukemia virus.
J. Virol.
64:5306-5316[Abstract/Free Full Text].
|
| 23.
|
Hart, C. E.,
C. Y. Ou,
J. C. Galphin,
J. Moore,
L. T. Bacheler,
J. J. Wasmuth,
S. R. J. Petteway, and G. Schochetman.
1989.
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells.
Science
246:488-491[Abstract/Free Full Text].
|
| 24.
| KewalRamani, V. N., B. Volsky, D. S. Kwon,
W. K. Xiang, J. Gao, D. Unutmaz, C. M. Hill, R. E. Sutton, and D. R. Littman. Unpublished data.
|
| 25.
|
Krishna, N. K.,
R. A. J. Weldon, and J. W. Wills.
1996.
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum.
J. Virol.
70:1570-1579[Abstract].
|
| 26.
|
Kulaga, H.,
T. Folks,
R. Rutledge,
M. E. Truckenmiller,
E. Gugel, and T. J. Kindt.
1989.
Infection of rabbits with human immunodeficiency virus 1. A small animal model for acquired immunodeficiency syndrome.
J. Exp. Med.
169:321-326[Abstract/Free Full Text].
|
| 27.
|
Kwak, Y. T.,
D. Ivanov,
J. Guo,
E. Nee, and R. B. Gaynor.
1999.
Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation.
J. Mol. Biol.
288:57-69[CrossRef][Medline].
|
| 28.
|
Landau, N. R.,
K. A. Page, and D. R. Littman.
1991.
Pseudotyping with human T-cell leukemia virus type I broadens the human Immunodeficiency virus host range.
J. Virol.
65:162-169[Abstract/Free Full Text].
|
| 29.
|
Landau, N. R.,
M. Warton, and D. R. Littman.
1988.
The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
Nature
334:159-162[CrossRef][Medline].
|
| 30.
|
Langley, R. J.,
G. A. Prince, and H. S. Ginsberg.
1998.
HIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus).
Proc. Natl. Acad. Sci. USA
95:14355-14360[Abstract/Free Full Text].
|
| 31.
|
Lingappa, J. R.,
R. L. Hill,
M. L. Wong, and R. S. Hegde.
1997.
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system.
J. Cell Biol.
136:567-581[Abstract/Free Full Text].
|
| 32.
|
Lingappa, J. R.,
R. L. Martin,
M. L. Wong,
D. Ganem,
W. J. Welch, and V. R. Lingappa.
1994.
A eukaryotic cytosolic chaperonin is associated with a high molecular weight intermediate in the assembly of hepatitis B virus capsid, a multimeric particle.
J. Cell Biol.
125:99-111[Abstract/Free Full Text].
|
| 33.
|
Lorès, P.,
V. Boucher,
C. Mackay,
M. Pla,
H. Von Boehmer,
J. Jami,
F. Barré-Sinoussi, and J. C. Weill.
1992.
Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection.
AIDS Res. Hum. Retroviruses
8:2063-2071[Medline].
|
| 34.
|
Mancebo, H. S.,
G. Lee,
J. Flygare,
J. Tomassini,
P. Luu,
Y. Zhu,
J. Peng,
C. Blau,
D. Hazuda,
D. Price, and O. Flores.
1997.
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
Genes Dev.
11:2633-2644[Abstract/Free Full Text].
|
| 35.
|
Moosmayer, D.,
H. Reil,
M. Ausmeier,
J. G. Scharf,
H. Hauser,
K. D. Jentsch, and G. Hunsmann.
1991.
Expression and frameshifting but extremely inefficient proteolytic processing of the HIV-1 gag and pol gene products in stably transfected rodent cell lines.
Virology
183:215-224[CrossRef][Medline].
|
| 36.
|
Morgenstern, J. P., and H. Land.
1990.
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.
Nucleic Acids Res.
18:3587-3596[Abstract/Free Full Text].
|
| 37.
|
Morrow, W. J.,
M. Wharton,
D. Lau, and J. A. Levy.
1987.
Small animals are not susceptible to human immunodeficiency virus infection.
J. Gen. Virol.
68:2253-2257[Abstract/Free Full Text].
|
| 38.
|
Newstein, M.,
E. J. Stanbridge,
G. Casey, and P. R. Shank.
1990.
Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tat-mediated trans activation in rodent cells.
J. Virol.
64:4565-4567[Abstract/Free Full Text].
|
| 39.
|
Onishi, M.,
S. Kinoshita,
Y. Morikawa,
A. Shibuya,
J. Phillips,
L. L. Lanier,
D. M. Gorman,
G. P. Nolan,
A. Miyajima, and T. Kitamura.
1996.
Applications of retrovirus-mediated expression cloning.
Exp. Hematol.
24:324-329[Medline].
|
| 40.
|
Page, K. A.,
N. R. Landau, and D. R. Littman.
1990.
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.
J. Virol.
64:5270-5276[Abstract/Free Full Text].
|
| 41.
|
Pauza, C. D.,
P. Trivedi,
T. S. McKechnie,
D. D. Richman, and F. M. Graziano.
1994.
2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.
Virology
205:470-478[CrossRef][Medline].
|
| 42.
|
Pollard, V. W., and M. H. Malim.
1998.
The HIV-1 Rev protein.
Annu. Rev. Microbiol.
52:491-532[CrossRef][Medline].
|
| 43.
|
Reina, S.,
P. Markham,
E. Gard,
F. Rayed,
M. Reitz,
R. C. Gallo, and O. E. Varnier.
1993.
Serological, biological, and molecular characterization of New Zealand White rabbits infected by intraperitoneal inoculation with cell-free human immunodeficiency virus.
J. Virol.
67:5367-5374[Abstract/Free Full Text].
|
| 44.
|
Sawada, S.,
K. Gowrishankar,
R. Kitamura,
M. Suzuki,
G. Suzuki,
G. Suzuki,
S. Tahara, and A. Koito.
1998.
Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors.
J. Exp. Med.
187:1439-1449[Abstract/Free Full Text].
|
| 45.
|
Skowronski, J.,
D. Parks, and R. Mariani.
1993.
Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.
EMBO J.
12:703-713[Medline].
|
| 46.
|
Spearman, P.,
R. Horton,
L. Ratner, and I. Kuli-Zade.
1997.
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism.
J. Virol.
71:6582-6592[Abstract].
|
| 47.
|
Speck, R. F.,
M. L. Penn,
J. Wimmer,
U. Esser,
B. F. Hague,
T. J. Kindt,
R. E. Atchison, and M. A. Goldsmith.
1998.
Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection.
J. Virol.
72:5728-5734[Abstract/Free Full Text].
|
| 48.
|
Tachibana, K.,
T. Nakajima,
A. Sato,
K. Igarashi,
H. Shida,
H. Iizasa,
N. Yoshida,
O. Yoshie,
T. Kishimoto, and T. Nagasawa.
1997.
CXCR4/fusin is not a species-specific barrier in murine cells for HIV-1 entry.
J. Exp. Med.
185:1865-1870[Abstract/Free Full Text].
|
| 49.
|
Trono, D., and D. Baltimore.
1990.
A human cell factor is essential for HIV-1 Rev action.
EMBO J.
9:4155-4160[Medline].
|
| 50.
|
Trono, D.,
M. B. Feinberg, and D. Baltimore.
1989.
HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.
Cell
59:113-120[CrossRef][Medline].
|
| 51.
|
Wei, P.,
M. E. Garber,
S. M. Fang,
W. H. Fischer, and K. A. Jones.
1998.
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
Cell
92:451-462[CrossRef][Medline].
|
| 52.
|
Welker, R.,
A. Janetzko, and H. G. Krausslich.
1997.
Plasma membrane targeting of chimeric intracisternal A-type particle polyproteins leads to particle release and specific activation of the viral proteinase.
J. Virol.
71:5209-5217[Abstract].
|
| 53.
|
Wiegers, K.,
G. Rutter,
U. Schubert,
M. Grättinger, and H. G. Kräusslich.
1999.
Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid.
Virology
257:261-274[CrossRef][Medline].
|
| 54.
|
Zhou, W.,
L. J. Parent,
J. W. Wills, and M. D. Resh.
1994.
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.
J. Virol.
68:2556-2569[Abstract/Free Full Text].
|
| 55.
|
Zhu, Y.,
T. Pe'ery,
J. Peng,
Y. Ramanathan,
N. Marshall,
T. Marshall,
B. Amendt,
M. B. Mathews, and D. H. Price.
1997.
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.
Genes Dev.
11:2622-2632[Abstract/Free Full Text].
|
Journal of Virology, April 2000, p. 3859-3870, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sun, J., Zheng, J. H., Zhao, M., Lee, S., Goldstein, H.
(2008). Increased In Vivo Activation of Microglia and Astrocytes in the Brains of Mice Transgenic for an Infectious R5 Human Immunodeficiency Virus Type 1 Provirus and for CD4-Specific Expression of Human Cyclin T1 in Response to Stimulation by Lipopolysaccharides. J. Virol.
82: 5562-5572
[Abstract]
[Full Text]
-
Monde, K., Maeda, Y., Tanaka, Y., Harada, S., Yusa, K.
(2007). Gp120 V3-dependent Impairment of R5 HIV-1 Infectivity Due to Virion-incorporated CCR5. J. Biol. Chem.
282: 36923-36932
[Abstract]
[Full Text]
-
Mehle, A., Wilson, H., Zhang, C., Brazier, A. J., McPike, M., Pery, E., Gabuzda, D.
(2007). Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding. J. Virol.
81: 13235-13241
[Abstract]
[Full Text]
-
Jin, J., Sturgeon, T., Chen, C., Watkins, S. C., Weisz, O. A., Montelaro, R. C.
(2007). Distinct Intracellular Trafficking of Equine Infectious Anemia Virus and Human Immunodeficiency Virus Type 1 Gag during Viral Assembly and Budding Revealed by Bimolecular Fluorescence Complementation Assays. J. Virol.
81: 11226-11235
[Abstract]
[Full Text]
-
Munk, C., Zielonka, J., Constabel, H., Kloke, B.-P., Rengstl, B., Battenberg, M., Bonci, F., Pistello, M., Lochelt, M., Cichutek, K.
(2007). Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells. J. Virol.
81: 7048-7060
[Abstract]
[Full Text]
-
Sun, Z., Denton, P. W., Estes, J. D., Othieno, F. A., Wei, B. L., Wege, A. K., Melkus, M. W., Padgett-Thomas, A., Zupancic, M., Haase, A. T., Garcia, J. V.
(2007). Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med.
204: 705-714
[Abstract]
[Full Text]
-
Tsurutani, N., Yasuda, J., Yamamoto, N., Choi, B.-I., Kadoki, M., Iwakura, Y.
(2007). Nuclear Import of the Preintegration Complex Is Blocked upon Infection by Human Immunodeficiency Virus Type 1 in Mouse Cells. J. Virol.
81: 677-688
[Abstract]
[Full Text]
-
Martina, Y., Marcucci, K. T., Cherqui, S., Szabo, A., Drysdale, T., Srinivisan, U., Wilson, C. A., Patience, C., Salomon, D. R.
(2006). Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection.. J. Virol.
80: 3135-3146
[Abstract]
[Full Text]
-
Coskun, A. K., van Maanen, M., Nguyen, V., Sutton, R. E.
(2006). Human chromosome 2 carries a gene required for production of infectious human immunodeficiency virus type 1.. J. Virol.
80: 3406-3415
[Abstract]
[Full Text]
-
Moore, P. L., Crooks, E. T., Porter, L., Zhu, P., Cayanan, C. S., Grise, H., Corcoran, P., Zwick, M. B., Franti, M., Morris, L., Roux, K. H., Burton, D. R., Binley, J. M.
(2006). Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1. J. Virol.
80: 2515-2528
[Abstract]
[Full Text]
-
Sun, J., Soos, T., KewalRamani, V. N., Osiecki, K., Zheng, J. H., Falkin, L., Santambrogio, L., Littman, D. R., Goldstein, H.
(2006). CD4-Specific Transgenic Expression of Human Cyclin T1 Markedly Increases Human Immunodeficiency Virus Type 1 (HIV-1) Production by CD4+ T Lymphocytes and Myeloid Cells in Mice Transgenic for a Provirus Encoding a Monocyte-Tropic HIV-1 Isolate. J. Virol.
80: 1850-1862
[Abstract]
[Full Text]
-
Hatziioannou, T., Martin-Serrano, J., Zang, T., Bieniasz, P. D.
(2005). Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells. J. Virol.
79: 15586-15589
[Abstract]
[Full Text]
-
Keppler, O. T., Allespach, I., Schuller, L., Fenard, D., Greene, W. C., Fackler, O. T.
(2005). Rodent Cells Support Key Functions of the Human Immunodeficiency Virus Type 1 Pathogenicity Factor Nef. J. Virol.
79: 1655-1665
[Abstract]